U.S. Markets closed
  • S&P Futures

    3,974.00
    -4.00 (-0.10%)
     
  • Dow Futures

    32,284.00
    -35.00 (-0.11%)
     
  • Nasdaq Futures

    12,833.25
    -20.75 (-0.16%)
     
  • Russell 2000 Futures

    1,733.00
    +0.50 (+0.03%)
     
  • Crude Oil

    69.22
    -0.74 (-1.06%)
     
  • Gold

    1,994.80
    -1.10 (-0.06%)
     
  • Silver

    23.21
    -0.05 (-0.20%)
     
  • EUR/USD

    1.0825
    -0.0012 (-0.1082%)
     
  • 10-Yr Bond

    3.4060
    -0.0940 (-2.69%)
     
  • Vix

    22.61
    +0.35 (+1.57%)
     
  • GBP/USD

    1.2264
    -0.0025 (-0.2024%)
     
  • USD/JPY

    130.3430
    -0.4460 (-0.3410%)
     
  • BTC-USD

    28,290.74
    +978.68 (+3.58%)
     
  • CMC Crypto 200

    618.53
    +21.07 (+3.53%)
     
  • FTSE 100

    7,499.60
    -67.24 (-0.89%)
     
  • Nikkei 225

    27,276.31
    -143.30 (-0.52%)
     

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

CHICAGO, May 09, 2022--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.

Poster presentation: "Development of Spherical Nucleic Acids Targeting SCN9A For the Treatment of Neuropathic Pain" – Poster Board Assignment Number: 54

Exicure will have the poster for viewing both in-person and virtually during the conference. Virtual posters will go live at the start of the conference and will be available to conference attendees for 2 weeks.

Exicure will add the poster to its website after the conference.

About Exicure

Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening.

For further information, see www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005183/en/

Contacts

Media:
Karen Sharma
MacDougall
781-235-3060
ksharma@macdougall.bio